Size matters: Establishing a cut‐off for rectal neuroendocrine neoplasm to predict recurrence and standardize surveillance guidelines
Digestive Endoscopy · 2025
DOI: 10.1111/den.15056 ↗Kurz gefasst
Leitlinie in der Zeitschrift Digestive Endoscopy, 2025. Verfasst von Seijong Kim und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Rectal Neoplasms, Neoplasm Recurrence, Local, Neuroendocrine Tumors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objectives
This study aimed to identify risk factors for recurrence of rectal neuroendocrine neoplasms, establish a cut‐off size for recurrence prediction, and standardize surveillance guidelines.
Methods
This retrospective study analyzed patients diagnosed with rectal neuroendocrine neoplasm at Samsung Medical Center from January 2007 to July 2021. Tumors were classified according to World Health Organization and European Neuroendocrine Tumor Society guidelines. The primary outcome was to determine the ideal cut‐off size for predicting recurrence.
Results
A total of 1011 patients (median follow‐up: 58 months) were included: 967 with grade (G) I neuroendocrine tumor (NET), 35 with GII NET, and 9 with neuroendocrine carcinoma. Disease‐free and overall survival were significantly better in GI NET than in GII and neuroendocrine carcinoma. For NET G1 patients undergoing endoscopic resection, a 0.7 cm cut‐off (area under the curve = 0.94) showed 100% sensitivity, 79% specificity, and no recurrence. In contrast, for lymphovascular invasion (LVI)‐positive, lymph node–negative NET G1 patients undergoing transanal endoscopic microsurgery/transanal excision or radical resection, an optimal cut‐off of 1.5 cm (area under the curve = 0.92) was identified. NET G2 had a 22.9% lymph node metastasis rate, with recurrence risk increasing with size.
Conclusions
For NET G1 tumors ≤0.7 cm without LVI following endoscopic resection, routine surveillance may not be necessary due to the minimal risk of recurrence. Similarly, for LVI‐positive, lymph node–negative NET G1 tumors that underwent surgical resection, surveillance may not be required if the tumor is ≤1.5 cm. Additionally, NET G2 tumors require regular follow‐up regardless of size to ensure favorable oncologic outcomes. These findings contribute to a risk‐based approach for surveillance, optimizing follow‐up strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Division of Gastroenterology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Korea.
- Department of Biopharmaceutical Convergence, Sungkyunkwan University, Seoul, Korea.
Zitieren
APA
Kim, S., Kim, E. R., Hong, S. N., Chang, D. K., Kim, Y. H., Shin, J. K., Park, Y., Huh, J. W., Kim, H. C., Yun, S. H., Lee, W. Y., & Cho, Y. B. (2025). Size matters: Establishing a cut‐off for rectal neuroendocrine neoplasm to predict recurrence and standardize surveillance guidelines. Digestive Endoscopy. https://doi.org/10.1111/den.15056
Vancouver
Kim S, Kim ER, Hong SN, Chang DK, Kim YH, Shin JK, et al. Size matters: Establishing a cut‐off for rectal neuroendocrine neoplasm to predict recurrence and standardize surveillance guidelines. Digestive Endoscopy. 2025. doi:10.1111/den.15056
BibTeX
@article{Kim2025,
author = {Kim, Seijong and Kim, Eun Ran and Hong, Sung Noh and Chang, Dong Kyung and Kim, Young-Ho and Shin, Jung Kyong and Park, Yoonah and Huh, Jung Wook and Kim, Hee Cheol and Yun, Seong Hyeon and Lee, Woo Yong and Cho, Yong Beom},
title = {Size matters: Establishing a cut‐off for rectal neuroendocrine neoplasm to predict recurrence and standardize surveillance guidelines},
journal = {Digestive Endoscopy},
year = {2025},
doi = {10.1111/den.15056}
}
EUVIMED